Eli Lilly’s one-patient early access to retatrutide leaves doctors seeking answers

Eli Lilly granted a single 79-year-old patient special access to retatrutide, an experimental obesity drug that has shown weight‑loss results comparable to bariatric surgery.

Since that decision, a handful of physicians have contacted the company asking for the same early‑access pathway for their patients. Several doctors report weeks of silence, with no guidance on eligibility or next steps.

One clinician finally received a reply after STAT reached out to Lilly, learning that his patient might qualify for the drug under the current program.

The episode highlights the uncertainty surrounding early‑access programs for unapproved obesity treatments and leaves many doctors without clear instructions on how to proceed.